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fisetin protects against cardiac cell 
death through reduction of RoS 
production and caspases activity
Sophie Rodius1*, niek de Klein2,3, céline Jeanty1, Héctor Sánchez-iranzo  4, isaac crespo5, 
Mark ibberson5, ioannis Xenarios  5,6,7, Gunnar Dittmar  1, nadia Mercader  4,8, 
Simone p. niclou  9 & francisco Azuaje  1,10*
Myocardial infarction (Mi) is a leading cause of death worldwide. Reperfusion is considered as an 
optimal therapy following cardiac ischemia. However, the promotion of a rapid elevation of o2 levels 
in ischemic cells produces high amounts of reactive oxygen species (RoS) leading to myocardial tissue 
injury. this phenomenon is called ischemia reperfusion injury (iRi). We aimed at identifying new and 
effective compounds to treat MI and minimize IRI. We previously studied heart regeneration following 
myocardial injury in zebrafish and described each step of the regeneration process, from the day of 
injury until complete recovery, in terms of transcriptional responses. Here, we mined the data and 
performed a deep in silico analysis to identify drugs highly likely to induce cardiac regeneration. 
Fisetin was identified as the top candidate. We validated its effects in an in vitro model of Mi/iRi in 
mammalian cardiac cells. fisetin enhances viability of rat cardiomyocytes following hypoxia/starvation 
– reoxygenation. it inhibits apoptosis, decreases RoS generation and caspase activation and protects 
from DNA damage. Interestingly, fisetin also activates genes involved in cell proliferation. Fisetin is thus 
a highly promising candidate drug with clinical potential to protect from ischemic damage following Mi 
and to overcome iRi.
Myocardial infarction (MI), the most common ischemic heart disease, is a leading cause of death worldwide1. It is 
a multifactorial disease: besides genetic predispositions, other parameters, e.g., smoking and obesity, are consid-
ered as prominent risk factors2. MI is most often caused by the blockade of a coronary artery after the rupture of 
an atherosclerotic plaque. This obstruction prevents blood supply (ischemia) to a part of the heart. Consequently, 
heart cells normally supplied with oxygen and nutrients by the impacted coronary artery die and are replaced by a 
fibrotic scar. While formation of this scar is crucial to prevent the rupture of the ventricular wall, excessive fibrotic 
response and reactive fibrosis in the uninjured myocardium can ultimately lead to left ventricular dysfunction, 
heart failure and death3.
During MI, myocardial cells are deprived from oxygen (hypoxia) and nutrients (starvation), leading to cell 
death. Apoptosis appears to play a predominant role in cardiomyocyte loss after MI, both in the infarcted and 
peri-infarcted myocardium. It determines infarct size, degree of left ventricular remodeling and onset of heart 
failure4,5. Two main apoptotic pathways can be observed: the intrinsic or mitochondrial pathway, and the extrin-
sic or death receptor pathway. Both are linked, can influence each other and converge on the same terminal 
signalling resulting in DNA fragmentation, protein degradation, formation of apoptotic bodies and ingestion 
by phagocytic cells6. The extrinsic apoptotic pathway is activated by extracellular signals via ligands interacting 
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with transmembrane death receptors, members of the tumor necrosis factor (TNF) superfamily7–9. The intrinsic 
apoptotic pathway is induced by different stimuli, such as hypoxia, deprivation of growth factors or oxidative 
stress. This pathway is activated when the mitochondrial membrane, whose integrity is regulated by BCL-2 family 
members, is permeabilized7,10,11. Caspases, a family of cytoplasmic endoproteases, are key regulators of apoptosis7. 
Following MI, cells suffer both from hypoxia and deprivation of growth factors, but also from oxidative stress due 
to the direct decrease in O2 level and the generation of reactive oxygen species (ROS)12,13. Mitochondria are the 
main consumers of O2 and the major producers of ROS in the cell. At physiological levels, ROS modulate various 
cellular processes, including: hypoxic response, growth factor signaling and inflammation. However, at higher 
concentration, ROS promote damages in DNA, proteins and membrane lipids, i.e., oxidative stress. Consequently, 
the cellular level of ROS must be highly regulated by the antioxidative capacity of the cell. In response to hypoxia, 
mitochondria modify their metabolism through modification of their respiratory chain and activation of hypoxia 
inducible factors (HIF) to keep ROS at relatively low levels13–15.
MI therapies aim at quickly restoring the blood flow to the heart, using either medications to dissolve the 
thrombotic clot or surgery, e.g., percutaneous coronary intervention (PCI). However, although reoxygenation is 
crucial for patient survival, reperfusion promotes a rapid elevation in O2 levels in ischemic cells, which induces a 
high production of ROS in mitochondria resulting in cardiomyocytes injury. This phenomenon, called ischemia 
reperfusion injury (IRI), can lead to cardiac remodeling and heart failure16,17. Because of these challenges and a 
relatively slow progress in the development of new drugs, there is a crucial need for new effective therapies to treat 
MI and overcome IRI.
To meet this clinically-relevant need, we implemented here a systematic approach for drug repositioning, 
which tapped into an extensive collection of expression signatures obtained from treated cancer cell lines. Our 
hypothesis was that a drug predicted to induce, in vitro, expression signatures observed at different key stages 
of heart regeneration in the zebrafish could also represent a promising compound for cardiac damage healing 
and IRI reduction. We selected the top candidate compound: fisetin, a flavonoid. Flavonoids, phytonutrients 
present in almost all kinds of fruits and vegetables, are polyphenolic compounds that fulfill many functions in 
plants18. They have recently emerged as powerful antioxidants providing health benefits in humans, protecting 
from degenerative diseases linked to oxidative stress such as cancer, diabetes and cardiovascular diseases19,20.
This study follows up our previous findings, where we studied the different steps of heart regeneration fol-
lowing myocardial injury in the zebrafish21. We were able to elucidate the dynamic gene co-expression network 
associated with key stages of heart regeneration following injury. Here, based on these data and the above-stated 
hypothesis, we developed a new computational method to find drugs capable to induce the transcriptional pat-
terns required for heart regeneration as observed in the zebrafish. We predicted and ranked candidate drugs, and 
performed experiments on mammalian cardiac cells subjected to an in vitro MI/IRI model to validate the effect of 
the top candidate drug: fisetin. Results indicate that fisetin is able to enhance cell viability of rat cardiomyocytes 
following hypoxia/starvation – reoxygenation, to protect from apoptotic cell death, by decreasing ROS generation 
as well as caspases activation, and to reduce DNA damage. These findings put forward fisetin as an excellent can-
didate for limiting cardiac damage due to ischemia following MI and for overcoming IRI.
Results
Identification of candidate compounds for repositioning through a systematic computational 
prediction strategy. We generated an integrated, statistically-ranked list of compounds positively (or neg-
atively) matched to the expression signatures identified in our heart regeneration gene expression dataset (Fig. 1, 
Methods). Our strategy is based on the exact estimation of probability distributions of rank product statistics. In 
our project, such signatures represented the dynamic transcriptional changes observed at each time point during 
the regeneration process as compared to 4 hours after injury: 5 time points, from 1 day to 90 days post-injury. 
We analyzed hundreds of gene expression signatures potentially relevant and sufficiently robust to mirror salient 
molecular states associated with the regeneration process. Based on a combination of computational processing 
and human expert analysis, we selected different sets of most relevant dynamic signatures for different post-in-
jury (and reference) time points. The size of these signatures ranged from a few dozen to hundreds of genes, and 
they were significantly enriched in diverse biological processes relevant to cardiac regeneration. Next, we focused 
on a set of 7 signatures that accurately and meaningfully represented key stages of the regeneration process. 
They included, for example, a signature representing expression changes at 1 day post-injury (in relation to 4 hrs 
post-injury).
We identified, ranked and curated a list of candidate compounds for repositioning. Such compounds were pre-
dicted to either induce or inhibit transcriptional programs that closely resemble those observed during the zebraf-
ish regeneration process. This resulted in the identification of fisetin as the top repositioning candidate (integrated 
p-value = 2.17E-11). We also identified withaferin A, a compound with diverse clinical applications including in 
cancer22, as negatively connected to cardiac cell regeneration in the zebrafish (integrated p-value = 1.80E-09). 
Thus, withaferin was predicted as a compound that is detrimental to cardiac cell regeneration by inducing, unlike 
fisetin, transcriptional signatures negatively correlated with the expression signatures observed during heart 
regeneration. Full list of the predicted positive and negative candidate drugs are available on https://lih-biomod.
lu/infused/.
Fisetin enhances viability of rat H9c2 cardiomyocytes following hypoxia/starvation - reoxy-
genation. In order to study the effect of fisetin on cell survival, we tested ten different concentrations of the 
drug (0, 5, 10, 15, 20, 30, 40, 60, 80 and 100 μM) on H9c2 cardiomyocytes. Cells were cultured under normoxia, 
in hypoxia/starvation (HS) or subjected to hypoxia/starvation – reoxygenation (HS/R)23,24. In each experiment, 
fisetin was applied during 24 h before cell analysis (see Methods). Cell viability was assessed by CyQuant Assay 
(Fig. 2A). Fisetin showed no sign of cell toxicity, even at the highest concentration (100 μM) and didn’t affect the 
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viability of cardiomyocytes cultured in normoxia. Compared to cells cultured in normoxia, HS/R and HS caused 
a decrease of 75% and 40% in cell survival, respectively. Fisetin significantly increased cell survival, with a peak 
at 15 μM where the drug restored cell viability by up to 70% for cells subjected to HS/R. For cells cultured in HS, 
Figure 1. Systems-level prediction of candidate drugs with potential to induce transcriptional responses 
as observed in vivo during heart regeneration in the zebrafish. We predicted candidate compounds for 
repositioning based on a new computational strategy that matches multiple heart regeneration expression 
signatures with drug-induced expression profiles in the Connectivity Map (CMap).
Figure 2. Fisetin enhanced the viability of H9c2 cardiomyocytes. (A) Survival tests were performed in 
normoxia, HS or HS/R experiments. Different concentrations of fisetin (from 0 to 100 μM) were tested. In 
normoxia experiments cells were cultured during 24 h in normal conditions, while in HS experiments cells 
were cultured in serum free DMEM at 0.5% O2, both in presence of the drug. In the HS/R experiments, cells 
were treated with fisetin following HS, during the whole reoxygenation phase. Cell survival was monitored by 
CyQuant assay. Results are expressed as the mean of three independent experiments performed in triplicate 
(error bars: SEM). (B) Effect of fisetin on cardiomyocytes viability upon HS/R treatment. Cell viability was 
measured in FACS by annexin V/PI staining: annexin V−/PI− cells were considered as viable. Normoxia: cells 
cultured under normoxia without fisetin (control group). HS/R: cells subjected to HS/R, treated with DMSO as 
vehicle control. HS/R + F: cells subjected to HS/R, treated with 15 μM fisetin. Results are expressed as the mean 
of three independent experiments. One-way ANOVA. Post-hoc analysis by Tukey. *P ≤ 0.05, ****P ≤ 0.0001.
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the peak in viability was at 20 μM with 90% of cell survival. On the contrary, withaferin A, decreased cell survival 
in a concentration-dependent manner, with an IC50 of 2.6 μM (Data not shown). DMSO, used as drug vehicle, 
didn’t affect cell viability. These results indicate that fisetin markedly enhanced survival of H9c2 cardiomyocytes 
following HS or HS/R. We focused our work on HS/R, our in vitro MI/IRI model. We therefore used the most 
effective concentration of 15 μM of fisetin in the subsequent experiments. We first validated the effect of fisetin 
on cell viability by FACS. H9c2 cardiomyocytes were cultured in serum free medium at 0.5%02 during 24 h to 
mimic hypoxia/starvation, then during 24 h in normoxic conditions in complete medium to mimic reoxygena-
tion. When indicated (HS/R + F) fisetin was applied during the whole reoxygenation phase. As expected, 15 μM 
of fisetin significantly reduced the cytotoxic effect of HS/R treatment (Fig. 2B).
Fisetin protects H9c2 cardiomyocytes from apoptotic cell death. In our experiments, survival/
viability was measured by CyQuant Direct assay, based on estimation of DNA content of healthy cells which 
can be directly correlated with cell number, or by annexin V/PI staining which labels apoptotic cells and allows 
to determine the number of remaining healthy cells in a given population. Since fisetin affected cell survival/
viability, i.e. cell numbers, we studied more precisely the effects of the drug on H9c2 cardiomyocytes prolifera-
tion and apoptosis following HS/R. Fisetin markedly increased proliferation of neonatal rat cardiomyocytes (2 
fold) measured by Ki67 staining (Fig. 3A), a result confirmed by cell cycle analysis showing a higher number of 
cells in S phase following fisetin treatment (Data not shown). The effect of the drug - increase in proliferation of 
0.6% - was however not statistically significant and too low to impact the global number of cells and explain the 
results obtained in the survival/viability experiments. In order to investigate whether fisetin was able to protect 
cardiomyocytes from HS/R induced cell death, we performed an annexin V/PI staining. Annexin V−/PI− cells 
were considered as viable cells, while annexin V+/PI− cells were considered as early apoptotic and annexin V+/
PI+ cells as late apoptotic (Fig. 3B). HS/R significantly increased apoptotic cell death compared to cells cultured 
in normoxia (from 6.9% to 15.5% for early apoptosis, and from 1.9% to 19.5% for late apoptosis, P ≤ 0.001). In 
the presence of fisetin, cell apoptosis in HS/R was markedly reduced: from 15.5% to 11% for early apoptosis and 
from 19.5% to 1.7% for late apoptosis (P ≤ 0.001). These results clearly show the protective effect of fisetin against 
HS/R-induced cardiomyocyte death.
fisetin regulates expression of genes related to cardioprotection and to cardiomyocytes prolif-
eration and maturation. We studied the effect of fisetin on cardioprotection, cardiomyocyte proliferation 
and cardiomyocyte maturation by qRT-PCR (Fig. 4). Of note, while we couldn’t detect any noticeable increase 
in sirt1 (sirtuin 1, a known fisetin target25) expression in our experimental model, we observed a significant 
Figure 3. Effect of fisetin on cardiomyocytes proliferation and apoptosis. Flow cytometry experiments 
were carried out to measure the amount of proliferating and apoptotic cells in each experimental group. (A) 
Proliferation of H9c2 cells assessed by Ki67 staining. Ki67+ cells are proliferating. Results are expressed as the 
mean of three independent experiments performed in triplicate. One-way ANOVA. Post-hoc analysis by Tukey. 
No significant difference: P > 0.05. (B) Dot plot representation of H9c2 apoptotic ratio measured by annexin V/
PI staining. Annexin V−/PI− cells were considered as viable, annexin V+/PI− cells were considered as early 
apoptotic and annexin V+/PI+ cells were considered as late apoptotic. Normoxia: control group, cells cultured 
under normoxia. HS/R: cells subjected to HS/R, treated with DMSO as vehicle control. HS/R + F: cells subjected 
to HS/R, treated with 15 μM fisetin. Results are expressed as the mean of three independent experiments 
performed in triplicate. Two-way ANOVA. Post-hoc analysis by Tukey. ***P ≤ 0.001.
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up-regulation of four cardioprotective genes following fisetin treatment: hmox1 (heme oxygenase 1), il6 (inter-
leukin 6, another known fisetin target26,27), fgf228,29 (fibroblast growth factor 2) and igf1r (insulin-like growth 
factor receptor 1). Moreover, while inhibition of the TGFβ1 pathway is known to protect H9c2 cardiomyocytes 
from IRI30–35, fisetin markedly decreased tgfβ1 expression. Interestingly, while the observed increase in Ki67+ 
cardiomyocytes did not reach statistical significance (Fig. 3A), we observed an increase in the expression of genes 
involved in cell proliferation including foxm1 (Forkhead Box M1), ccnd2 (cyclin D2), cdk6 (cyclin-dependent 
kinase 6), ccne1 and 2 (cyclin E), as well as cdk1 (cyclin-dependent kinase 1), whose activity is required for the 
cell cycle G1/S transition. This could explain the increased number of cardiomyocytes during the S phase of the 
cell cycle following fisetin treatment. Intriguingly, cdkn1a (p21) was highly up-regulated by fisetin in our exper-
iments. While this result may seem in contradiction with the apparent activation of the above mentioned G1/S 
transition, it is possibly related to the protective role of p21 against apoptosis and DNA damage36,37. Indeed, foxm1 
was also increased, and was recently shown to be a key regulator in DNA repair38. Finally, fisetin seemed to pro-
mote cardiomyocytes maturation, as indicated by the up-regulation of the cardiac muscle markers actc1 (α-actin) 
and actn2 (α-actinin), while elevation of cardiac progenitor markers like gata4 (GATA Binding Protein 4) and 
nkx2–5 (NK2 Homeobox 5) were either not detectable or not significant, respectively.
fisetin decreases RoS production. Hypoxia and reoxygenation are known to trigger an increase in ROS 
generation, mainly from mitochondria, leading to cell death. In our experiments fisetin protected against cell 
death. We therefore investigated its effect on ROS generation in H9c2 cardiomyocytes subjected to HS/R, using 
dihydrorhodamine 123 as ROS detection probe. ROS level was significantly elevated (1.5 fold, P ≤ 0.01) when 
cells were cultured in HS/R compared to cells cultured in normoxia (Fig. 5). In the presence of fisetin, ROS level 
in cells subjected to HS/R decreased to reach the level found in cells cultured in normoxia (P ≤ 0.01). Of note, 
fisetin also decreased ROS production in cardiomyocytes in HS experiments (data not shown). Altogether, fise-
tin prevents ROS elevation and may thus inhibit cell apoptosis by inhibiting ROS generation in cardiomyocytes 
subjected to HS/R.
Figure 4. Fisetin regulated a panel of genes related to cardioprotection, proliferation and maturation. Gene 
expression was assessed by qRT-PCR in cells cultured under normoxia, subjected to HS/R and treated with 
DMSO as vehicle control (HS/R) or subjected to HS/R and treated with 15 μM fisetin (HS/R + F) during 24 h. 
Results are expressed as the mean of four independent experiments. Statistical significance was determined 
using a one-way ANOVA corrected for multiple testing with a Tukey-Kramer as post-test (corrected 
p-value < 0.05). Statistically significant results are indicated in bold with a star. Fold change < 1: genes down-
regulated compared to normoxia (yellow). Fold change > 1: genes up-regulated compared to normoxia (blue).
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Fisetin inhibits caspases 8, 9 and 3 activation. Caspases are key regulator enzymes of both extrinsic 
and intrinsic pathways of apoptosis. In order to study the putative inhibitory effect of fisetin on caspases acti-
vation, we performed caspases activity assays to measure the activity of 3 different caspases in cardiomyocytes 
following HS/R: caspase 8 (specific of the extrinsic apoptosis pathway), caspase 9 (activated by the mitochondrial 
apoptosis pathway) and caspase 3 (a final executioner caspase activated through both apoptosis pathways). The 
number of cells expressing activated caspases 8, 9 and 3 was highly increased when H9c2 cells were cultured in 
HS/R compared to cardiomyocytes cultured in normoxia (Fig. 6): 2.2 fold of increase for caspase 8 (P ≤ 0.05); 2,8 
fold for caspase 9 (P ≤ 0.01) and 5 fold for caspase 3. Interestingly, fisetin was able to reverse this phenomenon, 
decreasing the number of caspase 8, 9 and 3 positive cells in cardiomyocytes cultured in HS/R down to the level 
found in cardiomyocytes cultured in normoxia. This indicates that fisetin is able to inhibit activation of caspases 
in both intrinsic and extrinsic apoptosis pathways in H9c2 cardiomyocytes subjected to HS/R.
fisetin protects from DnA damage. Hypoxia, starvation, ROS generation and caspases activation in cells 
lead to DNA damage. We thus investigated whether fisetin was capable of decreasing DNA damage in cardiomyo-
cytes subjected to HS/R, measuring 8-Hydroxyguanosine level as DNA damage marker. Intriguingly, we were not 
able to detect any DNA damage in cells following HS/R (data not shown). We hypothesized that cardiomyocytes 
may be able to repair DNA damage during the reoxygenation phase. Therefore, we aimed to detect DNA damage 
directly at the end of the HS period: the drug was applied during the whole hypoxia/starvation period after which 
Figure 5. Fisetin decreased ROS expression level in cardiomyocytes. The cell permeable, nonfluorescent 
dihydrorhodamine 123 probe enters the cell where it is oxidized by ROS to fluorescent rhodamine 123. 
Fluorescence intensity, proportional to ROS expression level, was measured by flow cytometry in each 
experimental group. Normoxia: control group; HS/R: cells subjected to HS/R, treated with DMSO as vehicle 
control; HS/R + F: cells subjected to HS/R, treated with 15 μM fisetin. Results are expressed as the mean of three 
independent experiments. One-way ANOVA. Post-hoc analysis by Tukey. **P ≤ 0.01.
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cells were immediately collected and analyzed (Fig. 7). Results indicate that HS generated DNA damage in cardio-
myocytes (2.9% of 8-Hydroxyguanosine positive cells when cardiomyocytes were cultured in normoxia compared 
to 34.6% following HS, P ≤ 0.001), while fisetin was able to reduce the proportion of damaged cells from 34.6% to 
25.1% (P ≤ 0.01). Thus, fisetin shows a protective effect against DNA damage.
Discussion
In a previous article, we studied cardiac regeneration in zebrafish using cryoinjury as MI model21. Unlike mam-
mals, zebrafish has the ability to fully regenerate its heart after severe damage. The whole regeneration is tightly 
regulated by the dynamic interplay of multiple genes. We coupled molecular biology techniques and in silico 
modelling to analyze the dynamic transcriptional responses associated with each step of the regeneration process. 
In the current work, we built on such data to predict drugs likely to activate cardiac regeneration following MI.
Here, we aimed to identify novel therapeutic associations between the transcriptional profiles observed during 
heart regeneration in the zebrafish and those induced by drugs in several cancer cell lines. This was done through 
the systematic statistical integration of such datasets. Our hypothesis was that potentially relevant candidate 
drugs are those capable to induce gene expression profiles in vitro that closely resemble gene expression profiles 
underlying heart regeneration in vivo. Our multiple-signature matching pipeline predicted fisetin, a flavonoid, as 
the top candidate.
Flavonoids recently appeared to be powerful antioxidants. This antioxidant effect is mediated through dif-
ferent mechanisms such as inhibition of enzymes involved in ROS generation, ROS scavenging, chelation of 
metal ions implicated in generation of free radicals or activation of antioxidant defenses18,19. Previous studies 
indicate that flavonoids offer protective effects against both the initiation and the progression of atherosclerosis, 
Figure 6. Fisetin inhibited activation of caspases 8, 9 and 3 in H9c2 cells. Caspases activity was assessed by 
flow cytometry using active caspase staining kits specific to caspase 8, 9 and 3, respectively. Dot plots represent 
the percentage of cardiomyocytes expressing activated caspase 8, 9 or 3. Normoxia: control group. HS/R: cells 
subjected to HS/R, treated with DMSO as vehicle control. HS/R + F: cells subjected to HS/R, treated with 15 μM 
fisetin. Results are expressed as the mean of three independent experiments. Two-way ANOVA. Post-hoc 
analysis by Tukey. **P ≤ 0.01, *P ≤ 0.05.
Figure 7. Fisetin protected cardiomyocytes cultured under HS from DNA damage. The proportion of 
damaged cells in each experimental group was measured by flow cytometry using the anti-8 Hydroxyguanosine 
antibody as DNA damage marker. Normoxia: control group. HS: cells in HS, treated with DMSO as vehicle 
control. HS + F: cells in HS, treated with 15 μM fisetin. Results are expressed as the mean of three independent 
experiments. ANOVA two factors (1: biological replicates/random; 2: Treatments). Post-hoc analysis by Tukey. 
***P ≤ 0.001, **P ≤ 0.01.
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which is one of the leading causes of MI39,40. They inhibit a key mechanism in the development of atheroscle-
rosis: the oxidation of low density lipoproteins (LDL). Moreover, they protect nitric oxide (NO) from oxida-
tion and increase its bioavailability, which helps restoring vascular endothelial function. Flavonoids also reduce 
inflammation by modulating pro-inflammatory cytokines like TNFα, decrease the expression of vascular cell 
adhesion molecules limiting thereby the recruitment of inflammatory cells to the arterial wall, inhibit platelets 
aggregation and enhance vaso-relaxation19,41–44. Based on their chemical structure, flavonoids can be divided in 
different subclasses45,46. Fisetin, a member of the flavonols family43,47, provides different beneficial effects through 
its anti-inflammatory48, antioxidant49, hypoglycemic50 or anti-obesity51 action. It is also known to have strong 
anti-cancer activity by inhibiting angiogenesis52, promoting cell cycle arrest in G2/M phase and by inducing apop-
tosis in cancer cells53,54. Moreover, it protects from coronary artery diseases via inhibition of atherosclerosis55.
Fisetin has the advantage of being non-toxic and cheap due to its wide availability as a natural product in a 
huge variety of fruits and vegetables. Since IRI is a major hurdle to cardiac recovery following MI, we also inves-
tigated fisetin’s protective properties against IRI for mediating cardiac recovery. We consequently validated its 
cardioprotective effects in mammalian cardiac cells subjected to an in vitro model of MI/IRI. In our model, cells 
were cultured under hypoxia and starvation to mimic MI, then exposed to normal conditions to mimic reoxygen-
ation before their analysis. Fisetin was supplied to the cells during the whole reoxygenation phase to simulate its 
application in the clinical setting. Results indicated that fisetin clearly enhanced survival of cardiomyocytes sub-
jected to MI/IRI. The drug was able to protect cells from apoptosis, decreased ROS generation, inhibited caspases 
activation and protected from DNA damage (Fig. 8).
The increased viability of cardiomyocytes in the presence of fisetin was mediated by the antiapoptotic effect of 
the drug. Fisetin inhibited expression of caspase 9, the initiator caspase specific of the intrinsic apoptotic pathway 
typically induced by hypoxia, starvation or oxidative stress, which are major consequences of HS/R. In view of 
the effect of fisetin on caspase 9 and ROS production, a deeper study of mitochondrial function following fise-
tin treatment is relevant to dissect the molecular pathways leading to fisetin’s anti-apoptotic effect. In addition, 
MI and IRI are also associated with elevated plasma level of TNFα56, one of the main activators of the extrinsic 
apoptotic pathway. Since fisetin inhibited expression of caspase 8, mediator of the extrinsic apoptotic pathway, we 
measured expression of TNFα in H9c2 cardiomyocytes culture medium after HS (6 h and over-night) and HS/R 
(4 h of reoxygenation) by ELISA. Intriguingly, we found that the expression of TNFα was too low to be detected in 
our experimental conditions (data not shown): expression of TNFα might be visible only after a very short reox-
ygenation period. Alternatively, fisetin treatment may instead affect regulation of other death receptors, e.g., FAS.
Furthermore, we investigated the effect of fisetin on cardioprotection. In agreement with our findings, 
Shanmugam et.al. recently showed the cardioprotective effect of fisetin using a Langendorff isolated heart perfu-
sion system57. In their paper, mice were pretreated with fisetin before heart excision and induction of ischemia on 
the perfused heart. They showed that fisetin pretreatment attenuated myocardial injury and blunted the oxidative 
stress via inhibition of glycogen synthase kinase 3β (GSK3β). Despite the differences between our two experi-
mental models - ex vivo experiments and pretreatment with fisetin prior to hypoxia vs in vitro experiments and 
Figure 8. Schematic representation of fisetin cardioprotective effects on neonatal rat cardiomyocytes. Fisetin 
protects cells from apoptosis by targeting both intrinsic and extrinsic apoptotic pathways. Fisetin also enhances 
proliferation by activating expression of cell cycle activators.
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fisetin treatment during the reoxygenation phase to mimic medication following surgery or dissolution of the 
thrombotic clot – our results are concordant. Our data also suggest that fisetin may have roles beyond cardiac 
protection, promoting cardiomyocyte proliferation and stimulating cardiomyocyte maturation. Further studies of 
cyclin - CDK complexes expression, degradation, phosphorylation activity and cellular localization would allow 
to better understand the effect of fisetin on cell cycle and DNA repair.
Summing up, we showed that fisetin protects cardiomyocytes from oxidative damage, and that further 
research could enable the establishment of protocols for myocardial regeneration. These findings demonstrate 
the value of fisetin as a candidate drug for the repositioning in MI treatment, by inhibiting ischemic damage 
following MI and overcoming IRI.
Methods
Brief protocol descriptions can be found hereunder. Detailed methods are described in the 
Supplementary Material Supplementary Methods.
prediction of candidate drugs for repositioning. Candidate compounds were identified through the 
integrated matching of zebrafish heart regeneration expression signatures against expression signatures obtained 
from drug-treated cell lines in the Connectivity Map database (CMap, build 2), which contains more than 7 K 
expression profiles representing more than 1.3 K compounds58. Before implementing that procedure, we mapped 
gene sequences from zebrafish to humans59 and we developed an algorithm for matching multiple regeneration 
signatures to CMap drug signatures. Our prediction pipeline provided a statistically-ranked, integrated list of 
compounds predicted to have positive, pro-regeneration potential (Supplementary Methods).
chemicals. Fisetin (3,3′,4′,7-Tetrahydroxyflavone, F4043) was purchased from Sigma-Aldrich (St Louis, MO, 
USA). Drug was dissolved in DMSO to a stock concentration of 100 mM. The final DMSO concentration in cell 
culture medium never exceeded 0.1%60.
cell culture. Neonatal rat H9c2 cardiac cells (ATCC® CRL-1446™) were purchased from ATCC (Rockville, 
MD, USA), routinely cultured at 37 °C 5%CO2 in Dulbecco’s Modified Eagle’s Medium DMEM (ATCC® 
30–2002™) supplemented with 10% Fetal Bovine Serum FBS (ATCC® 30–2020™) and 4 mM UltraGlutamine I 
(LOBE17–605E/U1, Westburg), and regularly tested for mycoplasma contamination. When sub-confluent, cells 
were detached with 1X Trypsin-EDTA Solution (ATCC® 30–2101™) to be subcultured.
Hypoxia/starvation – reoxygenation and drug treatment. Cells were cultured in normal conditions 
(20%O2/5%CO2 at 37 °C in DMEM 10%FBS) during 24 h. Hypoxia/starvation was then simulated by culturing 
the cells in serum free DMEM in a hypoxia incubator (0.5%O2, 5%CO2) for 24 h23. To mimic reoxygenation, cells 
were subsequently exposed to normal conditions (20%O2 and DMEM 10%FBS) for 24 h23,24. Fisetin, at 15 μM, was 
applied during the whole reoxygenation period. Control cells were treated with DMSO alone (final concentration 
of 0.025%) as vehicle control. Cells were harvested and analyzed at the end of the reoxygenation phase.
In the cell survival assay, a range of 10 different drug concentrations was tested (from 0 to 100 μM). For the 
DNA damage experiment, the drug was applied during the whole hypoxia/starvation period after which cells 
were immediately collected and analyzed. Normoxia control was performed by culturing the cells in normal 
conditions during the whole experiment.
cell survival assay. Cell survival was assessed using the CyQuant Direct Cell Proliferation Assay Kit 
(C35011) from Molecular Probes (OR, USA) according to the manufacturer’s protocol (Supplementary Methods).
cell proliferation assay. Experiments were performed by flow cytometry. Cells were harvested following 
drug treatment, washed, then stained with Ki67 antibody as described in Supplementary Methods.
Gene expression measurements. From 1 to 5 × 106 H9c2 cells were harvested following drug treatment 
and washed in 1x PBS before RNA extraction using TRI Reagent® (Sigma-Aldrich). Subsequent RNA isolation, 
qRT-PCR techniques and data analysis are described in Supplementary Methods.
cell death assay. Cell death was assessed by annexin V/PI staining followed by flow cytometry as described 
in Supplementary Methods.
Measurement of reactive oxygen species. Cells were harvested, washed in pre-warmed to 37 °C 1x PBS, 
and incubated for 30 min at 37 °C in the dark in a solution of pre-warmed 1x PBS - 10 μM Dihydrorhodamine 123 
(D23806, Invitrogen) at a cell density of 106 cells/mL. Cells were further washed in pre-warmed 1x PBS, resus-
pended in pre-warmed 1x PBS containing 1 μg/mL propidium iodide (P3566, Invitrogen) and analyzed by FACS 
on a BDFACS Canto™ Flow cytometer (BD Biosciences). We reported the mean intensity of three independent 
experiments acquired and analyzed using DIVA (BD Biosciences) and GraphPad Prism 7 (GraphPad).
caspases activity assay. Caspases activity assays were performed using the CaspGLOW™ Fluorescein 
Active Caspase Staining Kits (88–7004, 88–7005 and 88–7006 for caspase-3, 8 and 9 respectively, eBioscience), 
following the manufacturer’s protocol. Data were acquired and analyzed by FACS on a BDFACS Canto™ Flow 
cytometer (BD Biosciences) using DIVA (BD Biosciences) and GraphPad Prism 7 (GraphPad). We reported the 
mean intensity of three independent experiments.
Measurement of DnA damage. Drugs were applied during the whole hypoxia/starvation period. Cells 
were harvested immediately after and subjected to flow cytometry analysis. Cells were washed in HBSS, 2% 
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FBS, 10 mM HEPES pH7.4, stained with 1 µg/ml of LIVE/DEAD® Fixable Near-IR Dead Cell Stain Kit (L34975, 
Invitrogen) then fixed and permeabilized in BD Cytofix/Cytoperm™ solution (554722, BD Biosciences). Cells 
were then washed in BD Perm/Wash™ buffer (554723, BD Biosciences) and stained for 30 min in the dark with 
the FITC- Mouse Anti-8 Hydroxyguanosine antibody [15A3] (ab183393, Abcam) used at 1 µL/106 cells or the 
FITC- Mouse IGg2b antibody (21275533, Immunotools) as isotype control. We reported the mean intensity of 
three independent experiments. Data acquisition and analysis were performed using DIVA (BD Biosciences) and 
GraphPad Prism 7 (GraphPad).
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